Cell Therapy for Heart Failure
- 30 August 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 113 (6), 810-834
- https://doi.org/10.1161/circresaha.113.300219
Abstract
Despite significant therapeutic advances, the prognosis of patients with heart failure (HF) remains poor, and current therapeutic approaches are palliative in the sense that they do not address the underlying problem of the loss of cardiac tissue. Stem cell–based therapies have the potential to fundamentally transform the treatment of HF by achieving what would have been unthinkable only a few years ago—myocardial regeneration. For the first time since cardiac transplantation, a therapy is being developed to eliminate the underlying cause of HF, not just to achieve damage control. Since the initial report of cell therapy (skeletal myoblasts) in HF in 1998, research has proceeded at lightning speed, and numerous preclinical and clinical studies have been performed that support the ability of various stem cell populations to improve cardiac function and reduce infarct size in both ischemic and nonischemic cardiomyopathy. Nevertheless, we are still at the dawn of this therapeutic revolution. Many important issues (eg, mechanism(s) of action of stem cells, long-term engraftment, optimal cell type(s), and dose, route, and frequency of cell administration) remain to be resolved, and no cell therapy has been conclusively shown to be effective. The purpose of this article is to critically review the large body of work performed with respect to the use of stem/progenitor cells in HF, both at the experimental and clinical levels, and to discuss current controversies, unresolved issues, challenges, and future directions. The review focuses specifically on chronic HF; other settings (eg, acute myocardial infarction, refractory angina) are not discussed.Keywords
This publication has 157 references indexed in Scilit:
- Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heartEMBO Molecular Medicine, 2013
- Direct Comparison of Different Stem Cell Types and Subpopulations Reveals Superior Paracrine Potency and Myocardial Repair Efficacy With Cardiosphere-Derived CellsJournal of the American College of Cardiology, 2012
- Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialThe Lancet, 2011
- Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine modelsBasic Research in Cardiology, 2011
- Cardiospheres Recapitulate a Niche-Like Microenvironment Rich in Stemness and Cell-Matrix Interactions, Rationalizing Their Enhanced Functional Potency for Myocardial RepairThe International Journal of Cell Cloning, 2010
- Guided Cardiopoiesis Enhances Therapeutic Benefit of Bone Marrow Human Mesenchymal Stem Cells in Chronic Myocardial InfarctionJournal of the American College of Cardiology, 2010
- Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming FactorsCell, 2009
- Virus-free induction of pluripotency and subsequent excision of reprogramming factorsNature, 2009
- Endothelial progenitor cells in neovascularization of infarcted myocardiumJournal of Molecular and Cellular Cardiology, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006